Top Page
Stemcell United Ltd.
(Sydney:BP8)
Stemcell United Ltd. (BP8) vs. iShares MSCI Australia ETF (EWA)
Stemcell United Ltd. Business Overview & Revenue Model
Stemcell United Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 352.38K | 352.38K | 109.97K | 339.00 | 14.35M | 8.50M |
| Gross Profit | -678.01K | -678.01K | 18.27K | 339.00 | 2.29M | 1.54M |
| EBITDA | -1.45M | -1.45M | -1.76M | -2.49M | -2.49M | -2.41M |
| Net Income | -1.49M | -1.49M | -2.27M | -4.32M | -3.54M | -3.13M |
Balance Sheet | ||||||
| Total Assets | 541.00K | 541.00K | 691.84K | 2.10M | 7.16M | 10.11M |
| Cash, Cash Equivalents and Short-Term Investments | 152.74K | 152.74K | 134.82K | 1.14M | 685.56K | 5.26M |
| Total Debt | 0.00 | 0.00 | 508.64K | 0.00 | 1.30M | 1.76M |
| Total Liabilities | 2.01M | 2.01M | 1.97M | 1.19M | 2.44M | 3.83M |
| Stockholders Equity | -1.45M | -1.45M | -966.82K | 530.13K | 3.20M | 5.26M |
Cash Flow | ||||||
| Free Cash Flow | -932.18K | -932.18K | -1.26M | -1.49M | -4.93M | -1.78M |
| Operating Cash Flow | -929.81K | -929.81K | 0.00 | 0.00 | 0.00 | 0.00 |
| Investing Cash Flow | -2.37K | -2.37K | 185.33K | 6.29K | -914.21K | -418.04K |
| Financing Cash Flow | 962.99K | 962.99K | 697.04K | 1.38M | 281.27K | 6.25M |
Stemcell United Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$14.72M | -2.75 | ― | ― | -47.02% | 94.37% | |
44 Neutral | AU$3.71M | ― | ― | ― | ― | ― | |
41 Neutral | AU$2.54M | -0.46 | -487.52% | ― | 5.52% | 49.25% | |
40 Underperform | AU$10.57M | -1.79 | -166.70% | ― | ― | ― | |
40 Underperform | AU$2.17M | -4.33 | -28.49% | ― | ― | 46.43% | |
37 Underperform | AU$13.77M | -1.61 | -628.72% | ― | ― | 31.87% |
Stemcell United Ltd. Corporate Events
BPH Global Ltd has finalised an updated 2026–2027 R&D program under its “Project 6–7,” sharpening its focus on measuring, extracting and commercially recovering gold and silver from seaweed biomass. Following internal and external technical reviews, including input from its R&D consultant Gaia Mariculture and senior mining executives, the company is narrowing its previous broad minerals and rare earth elements work to concentrate on precious metals, informed by earlier assays that showed significant gold and silver accumulation in seaweed from the Johor Strait. The program will proceed via two parallel workstreams—ongoing harvesting and assay of seaweed from polluted and mineral-rich waters, including new sampling near a mining site in southern Malaysia, and in-house plus collaborative research on gold and silver extraction methods—aimed at accelerating commercialisation and potentially positioning BPH at the intersection of bio-based metal recovery and high‑value markets in commodities and advanced materials.
The most recent analyst rating on (AU:BP8) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.
BPH Global reported gross revenue of IDR 1.88 billion (about A$171,000) for the December trading period, bringing total sales since commencing operations in mid-May to roughly A$1.77 million as the company continues to build its Indonesian seaweed platform. December’s revenue fell sharply from November’s record month but remained within the historical range of the business’s first half-year of trading, with management attributing the dip to the seasonal rainy season in South Sulawesi, which constrained supply and pushed farm-gate prices above levels that allowed profitable trading under existing contracts. The company stressed that underlying demand and customer relationships remain intact and said it is maintaining its focus on scaling operations, strengthening its supply chain and preparing for expanded export activity in 2026, positioning the business for longer-term growth despite short-term seasonal volatility.
BPH Global Ltd, listed on the ASX under ticker BP8, has reported a change in its issued capital structure following the expiry of certain options. The company announced that 1,000,000 BP8AA options, which were due to expire on various dates and at various exercise prices, have lapsed unexercised as of 18 December 2025, resulting in the cessation of these securities and a corresponding adjustment to the company’s potential diluted capital base.
BPH Global Ltd has announced the issuance of 60,000,000 unquoted options, set to expire on December 2, 2027, with an exercise price of $0.006. This issuance is part of a previously announced transaction and is not intended to be quoted on the ASX, potentially impacting the company’s financial strategy and stakeholder interests.
BPH Global Ltd has announced the issuance of 113,750,000 unquoted securities, specifically options expiring on December 4, 2027, with an exercise price of $0.004. This issuance is part of previously announced transactions and is not intended to be quoted on the ASX, potentially impacting the company’s capital structure and providing strategic flexibility for future operations.
Stemcell United Ltd. has announced a change in the director’s interest, with Director Deepak Jha acquiring 15,000,000 Class A and 15,000,000 Class B Performance Rights as part of his remuneration package. This issuance of performance rights, approved by shareholders, reflects the company’s commitment to aligning director incentives with company performance, potentially impacting shareholder value and company governance.
BPH Global Ltd has announced the issuance of 275 million unquoted options with an exercise price of $0.004, set to expire on December 4, 2027. This issuance is part of previously announced transactions and is not intended to be quoted on the ASX, potentially impacting the company’s financial strategy and stakeholder interests.
BPH Global Ltd has announced the issuance of 76,125,000 unquoted options with an exercise price of $0.006, set to expire on December 2, 2027. This issuance is part of a previously announced transaction, and the options are not intended to be quoted on the ASX, indicating a strategic move to potentially raise capital or incentivize stakeholders.
BPH Global Ltd has issued 553,750,000 ordinary shares on November 27 and 28, 2025. This issuance falls under the exemption provided by Section 708A(5) of the Corporations Act 2001, allowing the on-sale of these securities without the need for disclosure. The company has complied with the necessary legal provisions, ensuring there is no excluded information required under the Act.
BPH Global Ltd has announced the quotation of 301,250,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code BP8. This move is part of previously announced transactions and is expected to enhance the company’s market presence and liquidity, potentially impacting its stakeholders positively.
BPH Global Ltd has announced a new issuance of 10,000,000 ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX) under the code BP8. This move is part of a previously announced transaction and is expected to enhance the company’s financial flexibility and market presence.
BPH Global Ltd, through its Indonesian subsidiary PT BPH Global Indonesia, has reported record growth in its seaweed sales for the period from 15 October to 14 November 2025, achieving gross sales of approximately A$551,627. This marks the highest monthly sales result to date, more than doubling the previous best performance. The company’s dual operational framework, which includes independent sales and a Sales Cooperation Agreement with PT Kebula Raya Bestari, has proven effective, with significant operational efficiency gains and strong domestic demand. The recent granting of an Indonesian Seaweed Export Licence is expected to further enhance revenue growth and margin improvement.
BPH Global Ltd is pioneering the development of seaweed-based formulations for male vitality and performance, securing a first-mover advantage in the men’s health and wellness market. The company, in collaboration with Gaia Mariculture, is focusing on creating a Natural Over-the-Counter supplement product with potential for clinical development. This initiative reflects BPH Global’s strategic focus on science-led innovation and addressing unmet needs in the wellbeing and nutraceutical sectors, potentially enhancing its market positioning and offering new opportunities for stakeholders.
BPH Global Ltd has appointed Ms. Ifat Mazouz to its Advisory Board to enhance its R&D commercialisation strategy. Ms. Mazouz brings nearly two decades of experience in marine biotechnology and aquaculture, strengthening the board’s capability to transition R&D programs from laboratory to commercial deployment. Her role will involve providing strategic advice on research oversight, sourcing new R&D opportunities, monitoring industry trends, and supporting strategic partnerships. This appointment is expected to align BP8’s research priorities with sustainable commercial outcomes, advancing its diversified R&D portfolio.
BPH Global Ltd, a company with a focus on Traditional Chinese Medicine-based natural formulations, has entered into an Exclusive Dealing Agreement with Denmark-based scientist Jo-an Refugio to evaluate a proprietary ginseng-based formulation aimed at enhancing male vitality and wellbeing. This agreement grants BPH Global a six-month exclusivity period to conduct due diligence and product testing, with the potential to acquire intellectual property rights and engage Jo-an as an R&D consultant. The formulation is part of BPH Global’s broader R&D initiative, exploring both natural over-the-counter products and evidence-based, clinically tested products.
BPH Global Limited announced a successful placement securing commitments to raise up to $1,100,000 from investors, enhancing its financial position. The company reported strong growth in its seaweed sales in Indonesia, demonstrating continued traction with both domestic and international customers, which supports its strategic focus on expanding its seaweed business operations.
BPH Global Ltd has signed a significant commercial framework agreement with the Indonesian Provincial Government’s company, Perumda Panca Raya, to secure seaweed supply and collaborate on bio-stimulant manufacturing in Maluku. This two-part agreement involves PPR Maluku supplying high-quality seaweed and partnering in the establishment of a bio-stimulant manufacturing facility, which will bolster BPH’s supply chain and support its strategic growth in the agricultural and marine sectors.
BPH Global Ltd has announced promising assay results from seaweed samples collected from the Johor Strait, revealing measurable concentrations of rare earth elements such as lanthanum, yttrium, and neodymium. These findings highlight the potential of seaweed to absorb and retain critical minerals, supporting the company’s goal to develop sustainable, seaweed-based pathways for mineral recovery and environmental remediation. The results could have significant implications for clean-tech applications and the emerging bio-minerals sector.
BPH Global Ltd reported a slight increase in sales for its Indonesian seaweed operations, achieving gross sales of A$226,947 for the period from 15 September to 14 October 2025. The company reached a significant milestone by obtaining a Seaweed Export Licence from the Indonesian Government, allowing it to export seaweed products directly, which is expected to enhance its market reach and operational flexibility. The Makassar warehouse is fully operational, supporting expanded processing and sales activities, and the company remains focused on building long-term customer relationships and expanding production volumes.
BPH Global Ltd has announced a proposed issue of up to 120,000,000 performance rights as part of a placement or other type of securities issue. This move is intended to enhance the company’s financial flexibility and potentially improve its market positioning by increasing its capital base, which could have significant implications for its operations and stakeholders.
BPH Global Ltd has announced a proposed issue of securities, which includes 113,750,000 options with an exercise price of $0.004 expiring two years from the date of issue, and 227,500,000 ordinary fully paid shares. The proposed issue date is set for November 21, 2025. This move is part of a placement or other type of issue, aimed at raising capital and potentially enhancing the company’s market position.
BPH Global Limited has announced its 2025 Annual General Meeting, which will be held on November 14, 2025, at Suite 5, Level 12, 530 Collins Street, Melbourne. Shareholders are encouraged to participate in the meeting, either in person or by proxy, as the business discussed will impact their shareholding. The company emphasizes the importance of shareholder votes and provides multiple methods for proxy voting to ensure participation.
BPH Global Ltd has commenced a new phase of its collaboration with Marchwood Laboratory Services to analyze seaweed samples from the Johor Strait for mineral and rare earth element concentrations. This study aims to deepen the understanding of how seaweed bio-accumulates minerals in response to environmental contamination, potentially enhancing its use in mineral recovery and environmental remediation.